Notch-related tumor markers were linked to prognosis in adenoid cystic carcinoma
A systematic review found associations between tumor markers and survival or recurrence, but differences in study methods restricted how much evidence could be pooled.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Notch-related mutations and protein-expression markers were associated with survival or recurrence in adenoid cystic carcinoma. These findings suggest possible value for estimating prognosis, but they do not show that using these markers improves treatment decisions or patient outcomes. The abstract also leaves important details about comparison groups and statistical uncertainty unspecified.
This abstract-based account cannot assess the precision of the reported associations: confidence intervals, follow-up periods and explicit reference groups for the hazard estimates are missing. The findings concern prognosis, without establishing a benefit from marker-guided care.
What the researchers examined
The review asked whether tumor characteristics measured at diagnosis were related to later outcomes. It considered mutation status and protein expression separately, with associations involving survival, recurrence or progression depending on the marker.
Why pooling was limited
Differences in study methods restricted pooling. Each marker's pooled analysis used only 2 studies, meaning those estimates drew on a narrower evidence base than the collection of studies included in the review.
The original publication
Deciphering NOTCH1 as a Biomarker in Adenoid Cystic Carcinoma: Insights From a Systematic Review With Meta-Analysis.
Slivar IS, Zanesco BA, Martins MD et al.
J Oral Pathol Med · 2025
- PubMed ID
- 40789681
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.